Skip to main content
HitGen Inc. logo

HitGen Inc. — Investor Relations & Filings

Ticker · 688222 ISIN · CNE1000040G3 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 629 across all filing types
Latest filing 2024-08-28 AGM Information
Country CN China
Listing Shanghai Stock Exchange 688222

About HitGen Inc.

https://www.hitgen.com/en

HitGen Inc. is a technology-driven research and development organization focused on the discovery of novel small molecule drug candidates. The company leverages its proprietary DNA-encoded library (DEL) platform, which features a collection of over 1.2 trillion diverse small molecules, to enable efficient hit identification and lead optimization. HitGen offers integrated drug discovery services, incorporating fragment-based drug discovery (FBDD) and structure-based drug design through its specialized research facilities. Its core operations include collaborative research partnerships with global pharmaceutical entities and the development of an internal pipeline of therapeutic programs. The platform combines synthetic chemistry, biology, and data informatics to streamline the identification of bioactive compounds for complex therapeutic targets.

Recent filings

Filing Released Lang Actions
成都先导药物开发股份有限公司2024年第三次临时股东大会会议资料
AGM Information Classification · 95% confidence The document is titled as meeting materials for the "2024 Third Extraordinary General Meeting of Shareholders" of Chengdu Lead Drug Development Co., Ltd. It contains detailed instructions for the meeting, agenda items, voting procedures, and a specific proposal regarding the reappointment of the company's 2024 financial and internal control audit firm. The content is focused on the meeting logistics and agenda rather than the actual audit report or financial statements. The document length is 3749 characters, which is relatively short and consistent with meeting materials rather than a full report. This matches the definition of AGM Information (AGM-R), which includes presentations and materials shared during the Annual or Extraordinary General Meeting. Therefore, the document should be classified as AGM Information (AGM-R).
2024-08-28 Chinese
成都先导药物开发股份有限公司2024年第二次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a formal announcement of the resolutions passed at an extraordinary shareholders' meeting held on June 28, 2024. It details the meeting attendance, voting results, and legal witness statements confirming the validity of the meeting and resolutions. There is no financial data, no report attached or referenced as being published, and no indication of a full report or presentation. The content fits the category of Declaration of Voting Results & Voting Rights Announcements, as it officially communicates the voting outcomes of a shareholders' meeting.
2024-06-28 Chinese
北京君合(成都)律师事务所关于成都先导药物开发股份有限公司2024 年第二次临时股东大会的法律意见书
Regulatory Filings
2024-06-28 Chinese
成都先导药物开发股份有限公司关于职工代表监事辞职及补选职工代表监事的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the resignation of an employee representative supervisor and the election of a new employee representative supervisor on the company's supervisory board. It includes details about the resignation, the election process, and the biography of the newly elected supervisor. There are no financial statements, earnings data, or regulatory certifications. The content relates to changes in the company's board/supervisory management structure. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and it is not a report publication or certification, so it is not RPA or RNS.
2024-06-28 Chinese
成都先导药物开发股份有限公司2023年年度权益分派实施公告
Notice of Dividend Amount Classification · 100% confidence The document is an announcement regarding the implementation of the 2023 annual dividend distribution by the company 成都先导药物开发股份有限公司. It details the dividend amount per share, relevant dates for record, ex-dividend, and payment, the approval of the dividend plan at the 2024 shareholders meeting, tax treatment for different shareholders, and instructions for dividend distribution. The document is relatively short (3256 characters) and focuses solely on dividend distribution details without containing full financial statements or comprehensive financial performance data. This matches the definition of a Notice of Dividend Amount (DIV), which announces dividend amounts, payment dates, and details for shareholders.
2024-06-14 Chinese
中国国际金融股份有限公司关于成都先导药物开发股份有限公司差异化分红事项的核查意见
Regulatory Filings
2024-06-14 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.